Morgan Stanley Maintains Overweight on ShockWave Medical, Lowers Price Target to $223
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on ShockWave Medical (NASDAQ:SWAV) but reduced the price target from $284 to $223.

December 04, 2023 | 4:12 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ShockWave Medical's Overweight rating is maintained by Morgan Stanley, but the price target is lowered from $284 to $223, indicating potential for growth but with moderated expectations.
While the Overweight rating suggests that Morgan Stanley still sees growth potential in ShockWave Medical, the reduction in the price target may reflect a reassessment of the company's near-term prospects, possibly due to market conditions or performance metrics. This could lead to a neutral short-term impact on the stock as investors digest the mixed signals of continued confidence in the company's performance against a lower expected valuation.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100